Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study

Journal of the American Society of Hypertension

Volumn 2, Issue 4, 2008, Pages 294-302

  Destro, Maurizio ^a   Luckow, Anders ^b   Samson, Mercedes ^c   Kandra, Albert ^d   Brunel, Patrick ^d  

^a Azienda Ospedaliera di Pavia   (Italy)

^b General Practice Office   (Denmark)

^c Associated Pharmaceutical Research   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Angiotensin receptor blocker; blood pressure; calcium channel blocker; combination

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS VALSARTAN; HYDROCHLOROTHIAZIDE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEAD INJURY; HEADACHE; HEART INFARCTION; HUMAN; HUMERUS FRACTURE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MULTICENTER STUDY; PERIPHERAL EDEMA; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SITTING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 47249088609     PISSN: 19331711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jash.2008.01.004     Document Type: Article

References (19)

1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., and He J. Global burden of hypertension: analysis of worldwide data. Lancet 365 (2005) 217-223
2. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo Jr. J.L., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 289 (2003) 2560-2572
3. Qureshi A.I., Suri M.F., Kirmani J.F., and Divani A.A. Prevalence and trends of prehypertension and hypertension in the United States: National Health and Nutrition Examination Surveys 1976 to 2000. Med Sci Monit 11 (2005) CR403-CR409
4. Antikainen R.L., Moltchanov V.A., Chukwuma Sr. C., Kuulasmaa K.A., Marques-Vidal P.M., Sana S., et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 13 (2006) 13-29
5. Wolf-Maier K., Cooper R.S., Kramer H., Banegas J.R., Giampaoli S., Joffres M.R., et al. Hypertension treatment and control in five European counties, Canada, and the United States. Hypertension 43 (2004) 10-17
6. European Society of Hypertension-European Society of Cardiology. 2007 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1105-1187
7. Bramley T.J., Gerbino P.P., Nightengale B.S., and Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm 12 (2006) 239-245
8. Andreadis E.A., Tsourous G.I., Marakomichelakis G.E., Katsanou P.M., Fotia M.E., Vassilopoulos C.V., et al. High-dose monotherapy vs. low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 19 (2005) 491-496
9. Kjeldsen S.E., Aksnes T.A., de la Sierra A., and Ruilope L.M. Amlodipine and valsartan: calcium channel blockers/angiotensin II receptor blockers combination for hypertension. Therapy 4 (2007) 31-40
10. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
11. Dahlöf B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
12. Mochizuki S., Dahlöf B., Shimizu M., Ikewaki K., Yoshikawa M., Taniquchi I., et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 369 (2007) 1431-1439
13. Poldermans D., Glazer R., Karagiannis S., Wernsing M., Kaczor J., Chiang Y.T., et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 29 (2007) 279-289
14. Williams B., Poulter N.R., Brown M.J., Davis M., McInnes G.T., Potter J.F., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
15. Philipp T., Smith T.R., Glazer R., Wernsing M., Yen J., Jin J., et al. Two multicenter, 8-week, randomized, double-blind placebo controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 29 (2007) 563-580
16. Sica D.A. Fixed-dose combination antihypertensive drugs: do they have a role in rational therapy?. Drugs 48 (1994) 16-24
17. Burges R.A., Gardiner D.G., Carter A.J., and Mckay F.F. Amlodipine. Long-term natriuretic and antihypertensive activity in spontaneously hypertensive rats with developing and established hypertension. Ann NY Acad Sci 522 (1988) 516-518
18. Munger M.A. Critical overview of antihypertensive therapies: what is preventing us from getting there?. Am J Manag Care 6 (2000) S211-S221
19. A 6-week Multi-Center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension. Novartis data on file 2006. http://clinicaltrials.gov/ct2/show/NCT00136851